Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711593 · ClinicalTrials.gov registry record · Phase 1
Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma
A Phase 1 study of Asthma and Allergies, sponsored by Andrew D. Luster, M.D.,Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT01711593 is a Phase 1 study of Asthma and Allergies that has completed, run by Andrew D. Luster, M.D.,Ph.D.. The registered enrollment target is 43 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01711593, a Phase 1 study of Asthma and Allergies, has completed, sponsored by Andrew D. Luster, M.D.,Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite advances in medications, allergic diseases, including allergic asthma continue to rise in prevalence. For this reason, there is a need for a better understanding of the mechanisms of allergic diseases and novel insights into modulating allergic inflammation. The investigators hypothesize that much remains to be learned about the behavior of T effector and T regulatory cells in allergic disease. Furthermore, the investigators hypothesize that novel mechanisms of allergic tolerance may exist, and elucidation of these mechanisms may provide insights into novel therapeutic strategies to control allergic diseases. The investigators will investigate the capacity for T cell tolerance induction in allergic subjects by a novel type of immune tolerizing dendritic cell (it-DC). The investigators will assess whether in vitro generated it-DCs have the capacity to induce antigen-specific T regulatory cells and suppress allergen-specific T effector cell function in vitro. Standardized Cat Allergen extract and Dust Mite Allergens will be used to generate changes in the airways that occur during exposure to allergen. For this investigation, the route of administration will be topical application of the titrated allergen to a bronchoscopically isolated subsegment of one lobe of one lung. The dose of biologic will be determined from prior skin-prick testing.
Interventions
- PROCEDURE Phlebotomy
- BIOLOGICAL Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711593
The ClinicalTrials.gov registry entry for NCT01711593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Andrew D. Luster, M.D.,Ph.D., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Phlebotomy is the first listed.
NCT01711593 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01711593 about?
NCT01711593 is a clinical study titled "Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma". Despite advances in medications, allergic diseases, including allergic asthma continue to rise in prevalence. For this reason, there is a need for a better understanding of the mechanisms of allergic diseases and novel insights into modulating allergic inflammation. The investigators hypothesize tha...
What is the current status of trial NCT01711593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-01. Estimated completion is 2016-09.
What conditions does trial NCT01711593 study?
This clinical trial studies the following conditions: Asthma, Allergies.
What interventions are being tested in trial NCT01711593?
The interventions under investigation include: Phlebotomy (PROCEDURE), Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage (BIOLOGICAL).
Who is sponsoring clinical trial NCT01711593?
This trial is sponsored by Andrew D. Luster, M.D.,Ph.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01711593 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.